InSilico and Eli Lilly Announce $2.75 Billion AI Drug Discovery Partnership
InSilico Medicine and Eli Lilly have entered a major AI drug discovery collaboration potentially worth $2.75 billion, with Lilly gaining exclusive rights to develop preclinical oral therapies. InSilico will receive $115 million upfront plus milestone payments and royalties. The deal reflects increasing pharmaceutical industry adoption of AI platforms to accelerate drug development.
InSilico Medicine has announced a global licensing and AI-driven drug discovery collaboration with Eli Lilly and Company in a deal that could be worth up to $2.75 billion. Under the agreement, Lilly will receive exclusive worldwide rights to develop, manufacture, and commercialize a portfolio of novel oral therapies currently in preclinical stages, with InSilico set to receive an upfront payment of $115 million.
The collaboration will see both companies jointly work on multiple research programs using InSilico's artificial intelligence platform alongside Lilly's drug development expertise. Additional milestone payments are tied to development, regulatory progress, and commercialization, with the deal also including tiered royalties on future product sales.
The partnership highlights growing interest among major pharmaceutical companies in leveraging AI to accelerate drug discovery. AI platforms are increasingly being used to identify targets, design molecules, and shorten development timelines, potentially reducing costs and improving success rates in bringing new therapies to market.
InSilico, which listed in Hong Kong in late 2025, focuses on integrating AI and automation into drug discovery across areas such as oncology, immunology, and metabolic diseases.